SILVER SPRING, Md., Dec. 23, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a ...
In DURATION-1, Drucker et al sought to compare a long-acting-release formulation of exenatide (2 mg, injected once weekly) with 10-µg exenatide injected twice per day in 295 patients with type 2 ...
The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), significantly improving access to diabetes treatment. The glucagon-like peptide-1 ...
Hopefully, the approval will help prevent shortages triggered by demand for injectable weight loss drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) There is still no ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. A large-scale clinical trial found ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. A large-scale clinical trial found ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback